Elena B. Elkin, PhD
Articles
May 15th 2011
Genomic Testing and Therapies for Breast Cancer in Clinical Practice
Jennifer S. Haas, MD, MSPH Kathryn A. Phillips, PhD Su-Ying Liang, PhD Michael J. Hassett, MD, MPH Carol Keohane, BSN, RN Elena B. Elkin, PhD Joanne Armstrong, MD, MPH Michele Toscano, MS
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: January 6th 2025 | Updated: January 22nd 2025
SPOTLIGHT: Shorter Duration of Venetoclax Is Possible for Some Patients With Newly Diagnosed AML
